✦ LIBER ✦

JAK2 and MPL Mutations in Myeloproliferative Neoplasms

✍ Scribed by Koppikar, Priya; Levine, Ross L.

Book ID: 120170419
Publisher: S. Karger AG
Year: 2008
Tongue: English
Weight: 244 KB
Volume: 119
Category: Article
ISSN: 0001-5792
DOI: 10.1159/000140634

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

JAK2 and MPL mutations in myeloprolifera

JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science

✍ Kilpivaara, O; Levine, R L 📂 Article 📅 2008 🏛 Nature Publishing Group 🌐 English ⚖ 114 KB

Laboratory Practice Guidelines for Detec

Laboratory Practice Guidelines for Detecting and Reporting JAK2 and MPL Mutations in Myeloproliferative Neoplasms

✍ Gong, Jerald Z.; Cook, James R.; Greiner, Timothy C.; Hedvat, Cyrus; Hill, Charl 📂 Article 📅 2013 🏛 American Society for Investigative Pathology 🌐 English ⚖ 593 KB

Uses and Abuses of JAK2 and MPL Mutation

Uses and Abuses of JAK2 and MPL Mutation Tests in Myeloproliferative Neoplasms

✍ Tefferi, Ayalew; Noel, Pierre; Hanson, Curtis A. 📂 Article 📅 2011 🏛 American Society for Investigative Pathology 🌐 English ⚖ 448 KB

LNK mutation studies in blast-phase myel

LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations

✍ Pardanani, A; Lasho, T; Finke, C; Oh, S T; Gotlib, J; Tefferi, A 📂 Article 📅 2010 🏛 Nature Publishing Group 🌐 English ⚖ 350 KB

Distinct patterns of cytogenetic and cli

Distinct patterns of cytogenetic and clinical progression in chronic myeloproliferative neoplasms with or without JAK2 or MPL mutations

✍ Laura Millecker; Patrick A. Lennon; Srdan Verstovsek; Bedia Barkoh; John Galbinc 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 309 KB

Novel mutations and their functional and

Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1

✍ Tefferi, A 📂 Article 📅 2010 🏛 Nature Publishing Group 🌐 English ⚖ 548 KB

Myeloproliferative neoplasms (MPNs) originate from genetically transformed hematopoietic stem cells that retain the capacity for multilineage differentiation and effective myelopoiesis. Beginning in early 2005, a number of novel mutations involving Janus kinase 2 (__JAK2)__, Myeloproliferative Leuke